Sage Extract for Memory: Efficacy and Safety Evidence

What the evidence shows

Small randomized studies report short-term improvements on selected memory and attention tests in healthy young and older adults.
The human evidence covers several different sage species and extraction methods; results from one preparation cannot be assumed to apply to all sage supplements.
One small four-month placebo-controlled trial in people with mild-to-moderate Alzheimer’s disease reported better cognitive-scale outcomes, but it does not establish durable clinical benefit or disease modification.
A 29-day study of a proprietary combined sage extract found selected working-memory and accuracy effects, but the result needs independent replication.
Short human trials have generally reported tolerability, while uncommon adverse events, long-term safety, interactions, and product-to-product differences remain insufficiently studied.
Laboratory cholinesterase findings explain a research hypothesis but are not themselves evidence of improved memory in everyday life.

What human research has actually tested

The human evidence does not concern one uniform product called sage extract. Trials have used Salvia officinalis (common sage), Salvia lavandulaefolia (Spanish sage), essential-oil preparations, hydroalcoholic leaf extracts, and a proprietary combination of sage polyphenols and terpenoids. These preparations are chemically different, so results from one cannot automatically be transferred to another.

The strongest recurring pattern is an effect on selected computerized memory or attention tasks, usually measured within hours of a single administration. One later study also tested a combined extract over 29 days. A 2023 review found that the clinical literature is promising but small, with inconsistent standardization and a need for larger, longer trials [5].

Laboratory findings, including inhibition of acetylcholinesterase or butyrylcholinesterase, provide a biological rationale for studying sage. They do not establish that a supplement improves memory in daily life, prevents cognitive decline, or changes the biology of Alzheimer’s disease.

Healthy young adults: acute memory signals

The early human evidence came from two small, double-blind, placebo-controlled crossover experiments in healthy young adults. Participants received different amounts of a standardized Spanish sage essential-oil preparation or placebo, with washout periods between visits. Memory was tested before administration and repeatedly over the same day using a computerized cognitive battery [1].

The clearest reported result was better immediate word recall under one tested condition in both experiments. The finding is relevant because the design included blinding, placebo comparison, repeated within-person testing, and counterbalanced treatment order. However, the studies were acute experiments with small groups, selected volunteers, and laboratory outcomes. They do not show a lasting memory improvement or a benefit for people with memory impairment.

The result should therefore be described as evidence of short-term modulation of a specific memory measure, not proof that Spanish sage broadly enhances cognition. Effects on delayed recall and other tasks were not uniformly established, and the essential-oil preparation is not interchangeable with an ordinary culinary herb or every capsule sold as sage.

Older and middle-aged healthy adults: broader testing, still limited duration

A randomized, double-blind, placebo-controlled, five-period crossover study examined a standardized Salvia officinalis extract in 20 healthy adults older than 65 years. Each participant experienced several extract conditions and placebo, with washout periods between visits. The computerized battery covered secondary memory, working memory, attention, and reaction-time outcomes [2].

The study reported an acute improvement in secondary-memory performance, including word-recognition and recall measures, with additional improvement in an attention-accuracy factor under a tested condition. This is useful evidence because the participants were older than those in the earliest Spanish sage studies and because the crossover design reduces some between-person variation. Its main weaknesses were the very small sample, short observation window, and uncertainty about how well the tested extract represents other sage products.

A larger parallel-group trial studied 94 healthy adults aged 30 to 60 years who received either a proprietary combination of S. officinalis polyphenols and S. lavandulaefolia terpenoids or placebo. Cognitive testing was performed acutely and again after 29 days. Improvements were reported on selected working-memory and accuracy measures, including spatial sequence, numeric working memory, and name-to-face recall tasks [4]. The study provides a useful longer-duration signal, but it tested a specific combination rather than sage in general and requires independent replication.

People with mild-to-moderate Alzheimer’s disease

The disease-population evidence is much thinner. One four-month, parallel-group, placebo-controlled trial enrolled 42 adults aged 65 to 80 years with mild-to-moderate Alzheimer’s disease. Participants were randomized to a Salvia officinalis leaf extract or placebo, and the main outcomes were changes in the cognitive subscale of the Alzheimer’s Disease Assessment Scale and the Clinical Dementia Rating sum of boxes [3].

At the end of the study, the extract group had statistically better scores than placebo on both reported outcome measures. The trial was randomized, placebo-controlled, and conducted across three centers, which are meaningful strengths. It was nevertheless a small study with a short follow-up and one particular extract. The results do not establish durable benefit, preservation of everyday functioning, prevention of progression, or effectiveness across the wider range of people living with Alzheimer’s disease.

The trial also does not justify treating a laboratory mechanism as a clinical conclusion. A cholinesterase-related hypothesis may explain why sage was studied, but it cannot substitute for repeated, independently replicated human trials with standardized products and clinically meaningful outcomes.

What the safety studies show

Across the cited human trials, sage preparations were generally tolerated during the short observation periods used. In the Alzheimer’s disease trial, the PubMed abstract reported no significant difference between groups in observed side effects; agitation was reported more often in the placebo group. The 2023 review also describes simple events such as vomiting and dizziness in a small number of participants [3,5].

These findings are reassuring only within the limits of the studies. Small trials can miss uncommon adverse events, and short studies cannot establish safety for prolonged use. Essential oils, concentrated extracts, and mixed botanical products may have different safety profiles from culinary sage. The composition and thujone content of commercial preparations can also vary, making broad safety claims difficult.

The available research provides little evidence about long-term use, pregnancy, breastfeeding, medication interactions, liver or kidney vulnerability, or use alongside drugs that affect cholinergic signaling. Those gaps are reasons to avoid interpreting the absence of a detected safety difference as proof of universal safety.

Bottom line: promising test effects, incomplete clinical evidence

Human research has established that selected sage preparations can influence performance on some memory, working-memory, attention, and accuracy tasks under controlled conditions. The evidence is most consistent for acute effects in healthy young or older adults, with one newer study suggesting that a defined combination may retain selected effects after several weeks.

The Alzheimer’s disease evidence consists primarily of one small randomized trial with a four-month follow-up. That result is important but not definitive, and it does not establish disease modification or a general clinical benefit. The preparations, species, extraction methods, and outcome measures differ too much for the studies to be combined into a simple claim about sage as a category.

The next useful studies would use chemically characterized preparations, preregistered primary outcomes, larger and more diverse populations, independent replication, longer follow-up, and measures that reflect everyday functioning as well as computerized test performance. Until then, the fairest conclusion is limited but credible human evidence for selected cognitive-test effects, with substantial uncertainty about durability, generalizability, and long-term safety.

Sources

About this article

NootroWorld publishes research summaries, not medical advice. This article describes what studies have and have not established; it does not tell you what to take. Supplements can interact with medication, pregnancy and existing health conditions, and study populations often differ from your own situation. Discuss any personal decision with a qualified healthcare professional.